Principles of N -Linked Glycosylation Variations of IgG-Based Therapeutics: Pharmacokinetic and Functional Considerations

Antibodies
Souad BouneLeslie A Khawli

Abstract

The development of recombinant therapeutic proteins has been a major revolution in modern medicine. Therapeutic-based monoclonal antibodies (mAbs) are growing rapidly, providing a potential class of human pharmaceuticals that can improve the management of cancer, autoimmune diseases, and other conditions. Most mAbs are typically of the immunoglobulin G (IgG) subclass, and they are glycosylated at the conserved asparagine position 297 (Asn-297) in the CH2 domain of the Fc region. Post-translational modifications here account for the observed high heterogeneity of glycoforms that may or not impact the stability, pharmacokinetics (PK), efficacy, and immunogenicity of mAbs. These modifications are also critical for the Fc receptor binding, and consequently, key antibody effector functions including antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Moreover, mAbs produced in non-human cells express oligosaccharides that are not normally found in serum IgGs might lead to immunogenicity issues when administered to patients. This review summarizes our understanding of the terminal sugar residues, such as mannose, sialic acids, fucose, or galactose, which influence therapeutic mAbs either ...Continue Reading

References

Dec 25, 2002·Chemistry & Biology·Terry D Butters
Oct 3, 2003·Proceedings of the National Academy of Sciences of the United States of America·Pam TangvoranuntakulElaine Muchmore
Sep 28, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rinpei NiwaKenya Shitara
Nov 23, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jennifer S LamStuart M Levitz
Dec 3, 2005·Biotechnology Progress·Jason HodoniczkyDavid C James
May 6, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shigeru IidaMitsuo Satoh
Aug 5, 2006·Science·Yoshikatsu KanekoJeffrey V Ravetch
Aug 29, 2006·Biotechnology and Bioengineering·Christopher K CrowellRobert I Scheinman
Nov 23, 2006·Methods in Enzymology·Santosh Kumar Patnaik, Pamela Stanley
Mar 17, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Eiji SuzukiMasakazu Toi
Aug 19, 2007·Nature Reviews. Immunology·Derry C Roopenian, Shreeram Akilesh
Sep 25, 2007·Biologicals : Journal of the International Association of Biological Standardization·Thomas A MillwardKurt Forrer
Feb 12, 2008·Current Protocols in Molecular Biology·L D Powell
Mar 29, 2008·Annual Review of Immunology·Falk Nimmerjahn, Jeffrey V Ravetch
Apr 19, 2008·Science·Robert M AnthonyJeffrey V Ravetch
Jul 9, 2008·Current Opinion in Immunology·T Shantha Raju
Nov 1, 2008·Glycobiology·Xiaoyu ChenGregory C Flynn
Dec 17, 2008·Proceedings of the National Academy of Sciences of the United States of America·Stephen L SazinskyK Dane Wittrup
Dec 17, 2008·Current Pharmaceutical Biotechnology·Alain BeckNathalie Corvaïa
Feb 28, 2009·Nature Reviews. Drug Discovery·Roy Jefferis
Nov 6, 2009·Current Opinion in Biotechnology·Yves Durocher, Michael Butler
Jan 13, 2010·MAbs·Naoko Yamane-Ohnuki, Mitsuo Satoh
May 7, 2010·Molecular Immunology·Gregory C FlynnZhongqi Zhang
May 19, 2010·Journal of Clinical Immunology·Robert M Anthony, Jeffrey V Ravetch
Jul 5, 2011·Biologicals : Journal of the International Association of Biological Standardization·Liming LiuThomayant Prueksaritanont
Apr 26, 2012·MAbs·T Shantha Raju, Robert E Jordan
Jul 4, 2012·Journal of the American Chemical Society·Wei HuangLai-Xi Wang
Jul 4, 2012·ACS Chemical Biology·M Jack BorrokGeorge Georgiou
Mar 16, 2013·Proceedings of the National Academy of Sciences of the United States of America·Nicole M OkeleyPeter D Senter
Jul 10, 2014·Current Opinion in Biotechnology·Michael Butler, Maureen Spearman

❮ Previous
Next ❯

Citations

Jul 27, 2021·Proteomics·Shay VimerMichal Sharon

❮ Previous
Next ❯

Methods Mentioned

BETA
glycosylation
transglycosylation

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Related Papers

Progress in Molecular Biology and Translational Science
Yiran ZhangXuexiao Ma
Nihon rinsho. Japanese journal of clinical medicine
Takeshi Harada, Masahiro Abe
Expert Opinion on Biological Therapy
Siao-Yi Wang, George Weiner
© 2022 Meta ULC. All rights reserved